Parathyroid imaging: how good is it and how should it be done?

Hypersecretion of parathormone in primary hyperparathyroidism is common, occurring in approximately 1 in 500 women and 1 in 2,000 men per year in their fifth to seventh decades of life. This has been suggested from the literature to be primarily the result of a parathyroid adenoma (80-85% of cases), hyperplasia involving more than 1 gland, usually with all 4 glands being involved (10-15% of cases), or the result, albeit rarely, of parathyroid carcinoma (0.5-1% of cases). Surgical removal of the hypersecreting gland is the primary treatment; this procedure is best performed by a skilled surgeon who would normally find the abnormality in 95% of cases. Imaging, however, should be used to identify the site of abnormality, potentially reducing inpatient stay and improving the patient experience. Functional imaging of parathyroid tissue using thallium was introduced in the 1980s but has largely been superceded by the use of (99m)Tc-labeled isonitriles. The optimum techniques have used (99m)Tc-sestamibi with subtraction imaging or washout imaging. A recent systematic review reported the percentage sensitivity (95% confidence intervals) for sestamibi in the identification of solitary adenomas as 88.44 (87.48-89.40), multigland hyperplasia 44.46 (41.13-47.8), double adenomas 29.95 (-2.19 to 62.09), and carcinoma 33 (33). This review does not separate the washout and subtraction techniques. The subtraction technique using (99m)Tc-sestamibi and (123)I is the optimal technique enabling the site to be related to the thyroid tissue when the parathyroid gland is in the neck in a normal position. If there is an equivocal scan then confirmation with high resolution ultrasound should be used. With ectopic glands, the combined use of single-photon emission computed tomography may then provide anatomical information to enable localization of the functional abnormality. In patients who have had surgical exploration by an experienced parathyroid surgeon in a unit with an experienced nuclear medicine team and negative sestamibi imaging, it is reasonable to image the patient with (11)C methionine. It is debatable whether patients with a high likelihood of secondary hyperparathyroidism should be imaged. The only possible justification for this is to exclude an ectopic site. There is no substitute for an experienced surgeon and an experienced imaging unit to provide a parathyroid service.

[1]  J. Norton,et al.  Localization of parathyroid adenomas in patients who have undergone surgery. Part I. Noninvasive imaging methods. , 1987, Radiology.

[2]  Antonio Cossu,et al.  The usefulness of neck pinhole SPECT as a complementary tool to planar scintigraphy in primary and secondary hyperparathyroidism. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  H. Fujii,et al.  Parathyroid imaging with technetium-99m sestamibi. , 2000, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  N. Obuchowski,et al.  Comparison of double-phase 99mTc-sestamibi with 123I-99mTc-sestamibi subtraction SPECT in hyperparathyroidism. , 1997, AJR. American journal of roentgenology.

[5]  W. Leslie,et al.  Parathyroid 99mTc-sestamibi scintigraphy: dual-tracer subtraction is superior to double-phase washout , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  S. Hain,et al.  Localization of parathyroid adenomas using 11C-methionine positron emission tomography , 2005, Nuclear medicine communications.

[7]  G. Irvin,et al.  Surgeon-performed ultrasonography as the initial and only localizing study in sporadic primary hyperparathyroidism. , 2006, Journal of the American College of Surgeons.

[8]  Brendan C. Stack,et al.  A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003 , 2005, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[9]  L. Delbridge,et al.  The value of oblique pinhole images in pre-operative localisation with 99mTc-MIBI for primary hyperparathyroidism , 2001, European Journal of Nuclear Medicine.

[10]  A. Giordano,et al.  Parathyroid imaging with 99Tcm‐tetrofosmin , 1996, Nuclear medicine communications.

[11]  R E Collins,et al.  Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  E. McDermott,et al.  Parathyroid localisation--current practice. , 2002, Journal of the Royal College of Surgeons of Edinburgh.

[13]  F. Palazzo,et al.  Minimally invasive parathyroidectomy , 2004, BMJ : British Medical Journal.

[14]  M. Pelizzo,et al.  Clinical role of 99mTcO4/MIBI scan, ultrasound and intra-operative gamma probe in the performance of unilateral and minimally invasive surgery in primary hyperparathyroidism , 2001, European Journal of Nuclear Medicine.

[15]  P. Sheedy,et al.  Results of reoperation for hyperparathyroidism, with evaluation of preoperative localization studies. , 1978, Surgery.

[16]  R. Taillefer,et al.  Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study) , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  J. Rastad,et al.  PET and parathyroid L-[carbon-11]methionine accumulation in hyperparathyroidism. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  R. Go,et al.  Primary hyperparathyroidism: preoperative parathyroid imaging with regional body FDG PET. , 1994, Radiology.

[19]  K. Rootwelt,et al.  Technetium-99m-tetrofosmin for parathyroid scintigraphy: a comparison with sestamibi. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  G. Wishart,et al.  Trends in surgical techniques. , 2003, Nuclear medicine communications.

[21]  M. O'Doherty,et al.  Parathyroid imaging: preoperative localization , 2003, Nuclear medicine communications.

[22]  D. Fuster,et al.  Biological factors influencing parathyroid localization , 2003, Nuclear medicine communications.

[23]  P M Wanet,et al.  Physical and clinical evaluation of high-resolution thyroid pinhole tomography. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  A. Moss,et al.  Parathyroid imaging: comparison of high-resolution CT and high-resolution sonography. , 1983, AJR. American journal of roentgenology.

[25]  J. Rastad,et al.  Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. , 2002, The Journal of clinical endocrinology and metabolism.

[26]  R. Udelsman Six Hundred Fifty-Six Consecutive Explorations for Primary Hyperparathyroidism , 2002, Annals of surgery.

[27]  L. Delbridge,et al.  Minimally invasive parathyroidectomy: 50 consecutive cases , 2000, The Medical journal of Australia.

[28]  M. Serio,et al.  Parathyroid glands: combination of (99m)Tc MIBI scintigraphy and US for demonstration of parathyroid glands and nodules. , 2000, Radiology.

[29]  ANNE KIRSTINE ARVESCHOUG,et al.  Presurgical Localization of Abnormal Parathyroid Glands Using a Single Injection of Tc-99m Sestamibi: Comparison of High-Resolution Parallel-Hole and Pinhole Collimators, and Interobserver and Intraobserver Variation , 2002, Clinical nuclear medicine.

[30]  M. Milas,et al.  Ultrasonography for the endocrine surgeon: a valuable clinical tool that enhances diagnostic and therapeutic outcomes. , 2005, Surgery.

[31]  L. Holder,et al.  Comparison of parathyroid imaging with technetium-99m-pertechnetate/sestamibi subtraction, double-phase technetium-99m-sestamibi and technetium-99m-sestamibi SPECT. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  M. O'Doherty,et al.  99Tcm sestamibi — a new agent for parathyroid imaging , 1989, Nuclear medicine communications.

[33]  A. Piotto,et al.  Radioguided surgery of primary hyperparathyroidism using the low-dose 99mTc-sestamibi protocol: multiinstitutional experience from the Italian Study Group on Radioguided Surgery and Immunoscintigraphy (GISCRIS). , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  R. Valkema,et al.  99mTc-tetrofosmin or 99mTc-sestamibi for double-phase parathyroid scintigraphy? , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  G. Ferlin,et al.  New perspectives in localizing enlarged parathyroids by technetium-thallium subtraction scan. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  William D Erwin,et al.  The value of 99mTc-sestamibi SPECT/CT over conventional SPECT in the evaluation of parathyroid adenomas or hyperplasia. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  E. Hindié,et al.  Parathyroid imaging using simultaneous double-window recording of technetium-99m-sestamibi and iodine-123. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  M. Ermani,et al.  Localization of parathyroid tumours in the minimally invasive era: which technique should be chosen? Population-based analysis of 253 patients undergoing parathyroidectomy and factors affecting parathyroid gland detection. , 2001, Endocrine-related cancer.

[39]  M. Whittaker,et al.  Ultrasound-guided unilateral neck exploration for sporadic primary hyperparathyroidism: is it worthwhile? , 1998, Annals of the Royal College of Surgeons of England.